Millennium Management’s European Biotech Acquisition Corp. Class A Ordinary Shares EBAC Stock Holding History

Millennium Management’s Portfolio EBAC Stock Details EBAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-593,018	Closed	-$5.99M	–	7336
2022 Q4	$5.99M	Sell	593,018 -3,554	-0.6%	-$35.5K	﹤0.01%	2658
2022 Q3	$5.91M	Hold	596,572	–	–	﹤0.01%	2727
2022 Q2	$5.84M	Sell	596,572 -2,555	-0.4%	-$25K	﹤0.01%	2635
2022 Q1	$5.83M	Buy	599,127 +478,025	+395%	+$4.65M	﹤0.01%	2761
2021 Q4	$1.17M	Sell	121,102 -9,013	-7%	-$87.7K	﹤0.01%	4268
2021 Q3	$1.26M	Sell	130,115 -18,900	-13%	-$183K	﹤0.01%	4433
2021 Q2	$1.45M	Buy	+149,015	New	+$1.46M	﹤0.01%	4301

Millennium Management's EBAC Position: Q1 2023 in Review

Millennium Management sold out of European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) in Q1 2023, closing a stake of 593,018 shares — an estimated $5.99M sold.

Millennium Management first reported a position in EBAC in Q2 2021 and held it in 7 quarters. The position peaked at $5.99M in Q4 2022. 0 funds tracked by Wall St. Rank hold EBAC as of Q1 2023.

Millennium Management reported no remaining European Biotech Acquisition Corp. Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Millennium Management sold 593,018 European Biotech Acquisition Corp. Class A Ordinary Shares shares in Q1 2023, an estimated $5.99M.
Millennium Management first reported a position in European Biotech Acquisition Corp. Class A Ordinary Shares in Q2 2021 and held it in 7 quarters.
Millennium Management's European Biotech Acquisition Corp. Class A Ordinary Shares position peaked at $5.99M in Q4 2022.
0 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Class A Ordinary Shares as of Q1 2023.

Based on Millennium Management's 13F filing for Q1 2023, filed 15 May 2023.